17 Mar

GoodGut to take part in a panel discussion on microbiota at BIO-Europe Spring 2017

GoodGut to take part in a panel discussion on microbiota at BIO-Europe Spring 2017

Bio-EuropeSpring2017

GoodGut will be an active participant in the eleventh edition of BIO-Europe Spring, to be held in Barcelona from 20th to 22nd March. BIO-Europe Spring is the most important European conference for the biotechnology and pharmaceutical industry, this year expecting to welcome over 1,400 companies from the sector, with over 2,400 participants. The 2017 event is organised by EDB Group with the collaboration of Biocat and ACCIÓ.

The Medical Director of GoodGut, Dr Xavier Aldeguer, and the CEO, Dr Mariona Serra, will take part in the panel discussion Key Considerations in Microbiome Partnering, on 20th March at 4 pm, with Michel de Baar from MSD, Eric de La Fortelle from Seventure and Mike Ward from Informa Pharma Insights.

The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is partnerships. The current state of play means emerging companies are often looking for specific expertise or experience in their partners, often influenced by the variety of approaches under different regulatory jurisdictions or financial structures. Join this panel to hear how emerging microbiome companies identity their preferred partners and what pharma companies and funders are able to bring to the panel discussion.

GoodGut considers intestinal microbiota to be a determining factor in the appearance of digestive diseases and the focus of its research and the new non-invasive tests (in clinical trial phase) which will help to improve early diagnosis.

Over the three days, GoodGut will also take the opportunity to hold private 30-minute meetings with other international executives and business developers. The conference is expected to lead to 12,500 meetings of this type.

Barcelona previously hosted the conference in 2010 and 2013 and the fact that it is doing so again reasserts Catalonia’s strategic position as a pioneering international business centre for the life sciences and healthcare.

Photo: BIO-Europe Spring Barcelona 2013 – Biocat

15 Mar

The New Non-Invasive Test from GoodGut, at the 12th Congress of ECCO

The New Non-Invasive Test from GoodGut, at the 12th Congress of ECCO

With the theme Advancing Knowledge, Improving Care, Barcelona played host to the 12th Congress of ECCO (European Crohn’s and Colitis Organisation) on inflammatory bowel disease (IBD). This congress is an unmissable event for scientists and medical specialists from around the world wishing to explore the latest research and clinical care trends in the field.

GoodGut, which began clinical trials of a non-invasive system for detecting IBD (RAID-CD) at Dr. Josep Trueta University Hospital in Girona, with a population of 100 patients, was one of the companies taking part in the congress. IBD includes both Crohn’s disease and ulcerative colitis.

Specifically, two scientific posters were presented by Joan Amoedo, researcher in a team through the Industrial Doctorates Scheme of the Generalitat of Catalonia. The most relevant result on the first poster, which was one of the most consulted, described the excellent capacity of the phylogroups (PHGI and PHGII) to discriminate between ulcerative colitis and Crohn’s disease patients exclusively affecting the colon.

The most significant result on the second poster was that the PHGI and PHGII have proven to be good active phase indicators, providing for the possibility of a different activity marker for each disease. In this case, as Joan Amoedo explains, “it was detected that an increased number of patients was required to validate the markers as a parameter of activity for both diseases”. As a result, the corresponding clinical trials for the differential diagnosis and monitory of inflammatory bowel disease, and the use of these markers to predict the response to anti-TNF treatments such as post-operative recurrence are currently being conducted at Dr. Josep Trueta University Hospital in Girona, Bellvitge University Hospital and Germans Trias i Pujol University Hospital.

Both diseases are chronic and tend to appear in young people (before the age of 30). An estimated 2.5–3 million people in Europe are affected by IBD. In Spain, Crohn’s disease affects around 137.2 people out of every 1000 and, according to ACCU, ulcerative colitis is more common than Crohn’s disease (58% compared to 42%).

Currently IBD is diagnosed with the support of clinical indices and inflammatory parameters such as calprotectin. However these parameters are not sufficiently accurate and generally do not determine when there will be a flare-up of the disease. As a result, a colonoscopy is always necessary, despite being a highly invasive technique with risk of death. In order to diagnose and monitor these chronic diseases the GoodGut system makes it possible to consider one kilogram of bacteria living inside the body which, when unbalanced, are responsible for causing inflammatory response. The RAID-CD can thus be used for non-invasive identification in faeces of the specific microbiological signature for each disease and the degree of dysbioisis can be measured to monitor the disease correctly and provide effective treatment guidelines.

 

 

11 Mar

Mariona Serra, one of the many inspiring women behind Catalunya Emprèn

Mariona Serra, one of the many inspiring women behind Catalunya Emprèn

EmprenCat_MarionaSerra

Dr Mariona Serra, co-founder and CEO of GoodGut, is one of the women who inspired the work of Catalunya Emprèn in 2016. Her contribution was mentioned within the scope of FemTalent Fòrum 2017, at a round table held on 20 January in Barcelona and led by Montserrat Sànchez, programme communication manager at Catalunya Emprèn; Almudena Castillo, programme management manager at Catalunya Emprèn and Maria José Blanco, manager of the Barcelona Activa Women Entrepreneurs School. Two of the other guests were from the field of health and life sciences: Dr Teresa Tarragó of Iproteos and Raquel Riera of Biocat.

Female talent is becoming a force to be reckoned with in Catalonia. According to figures from Xarxa Emprèn, a public-private business start-up advice and support network, for 2015, out of all the entrepreneurs advised, 50.21% were women and 49.79% were men. And out of the businesses created, 46.73% were the initiative of women.

Mariona Serra, who has a doctorate in pharmacology, started her entrepreneurial life after a post doctorate degree at Biomedical Research Institute of Girona (IDIBGI), then later an Advanced Management Programme at Iese to complement it. In 2014, Serra founded the biotechnology company GoodGut with Dr Xavier Aldeguer and Dr Jesús García-Gil. She is currently also a member of the Social Council of the Universitat Autonòma de Barcelona, where she chairs the University-Business Committee. Her motto, as she explains in this Biocat interview, is “do business in a team and create your own virtuous circle”.